J&J Puts U.S. Coronary Stent Market Share At 15-18% Exiting Second Quarter
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson estimates its share of the U.S. coronary stent market at 15-18% exiting the second quarter on the strength of its BX Velocity stent.
You may also be interested in...
Johnson & Johnson/Cordis
Company estimates it currently has "just a little over 20%" of the U.S. coronary stent market and approximately 24% in Europe. "Every quarter we continue to gain share and we're pretty optimistic that we are in the same mode for the rest of this year," Group Chaiman Robert Croce comments. The firm had originally put its share of the U.S. coronary stent market at 15-18% (1"The Gray Sheet" July 24, 2000, p. 15). While it credits increased sales of the BX Velocity for the growth, the company intends to initiate a November launch of a heparin-coated version. Mounted on a Raptor delivery system, the product is indicated for sub-acute thrombosis and will sell at a 15-20% premium over the uncoated version
Johnson & Johnson/Cordis
Company estimates it currently has "just a little over 20%" of the U.S. coronary stent market and approximately 24% in Europe. "Every quarter we continue to gain share and we're pretty optimistic that we are in the same mode for the rest of this year," Group Chaiman Robert Croce comments. The firm had originally put its share of the U.S. coronary stent market at 15-18% (1"The Gray Sheet" July 24, 2000, p. 15). While it credits increased sales of the BX Velocity for the growth, the company intends to initiate a November launch of a heparin-coated version. Mounted on a Raptor delivery system, the product is indicated for sub-acute thrombosis and will sell at a 15-20% premium over the uncoated version
Boston Scientific Consolidation Aimed At Saving $250 Mil. Annually By 2003
Boston Scientific's decision to close three of its manufacturing facilities over the next 18 months combined with the elimination of 1,000 positions is expected to contribute to annual cost savings of $250 mil. by 2003.